Serum soluble interleukin 2 receptor (sEL2R) was measured in patients with active and inactive systemic lupus erythematosus (SLE).
The concentration of sIL2R was higher in inactive SLE than in normal controls and was significantly increased in active compared with inactive SLE. When patients with active SLE were followed up serially it was found that the sIL2R concentration fell when the disease became inactive. There was no statistically significant association between sIL2R and the grades of disease activity, however.
In patients with either active or inactive SLE and infection the sIL2R concentration was much higher than in those without infection. Chronic infection (tuberculosis or candida) was associated with a much higher concentration of sIL2R than pyogenic or herpes zoster infection. The sIL2R concentration helps to distinguish infection in patients with SLE.
Systemic lupus erythematosus (SLE) is the prototype of autoimmune disease arising from defective immunoregulation.' Various immunopathogenetic mechanisms have been described and a wide array of observable defects proposed, debated, and rebutted.25
Soluble interleukin 2 receptor (sIL2R) is a molecule derived from the membrane interleukin 2 receptor.6 7 It is easily measurable in serum and body fluids by enzyme linked immunosorbent assay (ELISA)6 and has been reported to be increased in SLE,"'0 rheumatoid arthritis,81 infection,'2 and lymphoma.3 14 We investigated the usefulness of sIL2R in defining activity and major organ involvement in SLE, and, particularly, whether sIL2R can distinguish SLE disease activity from infection. C4, serum creatinine, urinary protein, haemoglobin, platelet count) and given a score as follows: 0=absence of symptoms, signs, or normal laboratory values; l=moderate and 2=severe symptoms, signs, or laboratory abnormalities. Disease activity was classified as in remission, mild, moderate, and severe when the score was 0, 1-10, 11-20, and >20 respectively. Controls, aged 12-55, were selected from hospital patients and had no evidence of infection or inflammation. They comprised 14 patients with congenital heart disease without evidence of infective carditis for at least six months, six patients with minimal diazepam overdose, and three patients with non-peptic ulcer dyspepsia.
Serum samples were also collected from the cohort of patients who developed major infections during the period of follow up. Their disease status was assessed and classified as inactive or active using the above system.
DETECTION OF sIL2R
Serum sIL2R was determined using a sandwiched ELISA (Cell-free, T (fig 1) , suggesting that lymphocyte activation may still be present even though the disease is considered inactive by clinical criteria, but the concentration of sIL2R was much higher in active SLE. The sIL2R concentration was less than 500 units/ml in all controls, 41/50 (82%) patients with inactive SLE, and 12/50 (24%) with active SLE (table 3) . When sIL2R was first described it was hoped that it might prove to be a sensitive marker of disease activity or early clinical relapse in SLE. Our serial study of 27 patients showed that in all but one patient the sILR2 concentration fell with control of the active disease (fig 2) , and from the sIL2R concentration we could, to some extent, distinguish active from inactive disease. When disease activity was divided into three subgroups, however: mild, moderate, severe, sIL2R concentrations did not correlate with the activity of the disease ( In patients with SLE both disease activity and infection can cause fever. It has been reported that CRP can distinguish between these causes.25 It is not a completely reliable marker, however, as the CRP fails to rise in some cases of severe infection and, on the other hand, many rise to a level indicative of infection in the presence of active disease alone (unpublished observations). The concentration of sIL2R in active SLE accompanied by infection is well above 1000 U/ml (especially for those with tuberculosis or fungal disease), whereas in those with active disease with no infection the concentration of sIL2R is only around 1000 U/ml. Similarly, patients with inactive SLE have a low concentration of sIL2R, whereas in the presence of infection the concentration soars markedly. Thus chronic infection is associated with a much raised sIL2R in both active and inactive SLE (table 3) .
A comparison of the causes of infection showed that chronic infection (tuberculosis of fungal infections) was associated with a much higher concentration of sIL2R than other infections, such as pyogenic or herpes zoster infection (p<0c000). A further study of patients with tuberculosis who are not receiving immunosuppressive treatment is under way. It has been found that patients with active tuberculosis have raised sIL2R, which falls with treatment and sputum conversion, but in two patients with refractory tuberculosis their sIL2R concentrations remain markedly raised (unpublished observations). These results support the findings of this study and show that sIL2R concentration can help to distinguish chronic infections from other infections-an important distinction because tuberculous or fungal infection are important causes of morbidity in patients with SLE and may be associated with substantial mortality if treatment is delayed. A limitation of our study is the small number of patients with inactive SLE and infection, but most patients with inactive SLE are receiving minimal steroid or immunosuppressive treatment and development of serious infection is fairly unusual. Most patients with inactive SLE have an sIL2R concentration .500 units/ml (table 3) and therefore, an sIL2R concentration > 1500 units/ml strongly suggests the presence of infection (x2=49-53, p<0001). A detailed search for infection is mandatory, especially for tuberculosis and fungus. 
